sorafenib has been researched along with Hypertension, Portal in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Y; Li, A; Luo, R; Zhu, Y | 1 |
| Bosch, J; Fernandez, M; Garcia-Pras, E; Mejias, M; Miquel, R; Tiani, C | 1 |
| Bruix, J; Shah, VH | 1 |
| Heller, J; Hennenberg, M; Kohistani, AZ; Sauerbruch, T; Stark, C; Trebicka, J | 1 |
| Angermayr, B; Gangl, A; Mitterhauser, M; Peck-Radosavljevic, M; Reiberger, T; Rohr-Udilova, N; Schwabl, P | 1 |
| Fischer, HP; Granzow, M; Heller, J; Hennenberg, M; Klein, S; Kohistani, Z; Körner, C; Krämer, B; Nischalke, HD; Sauerbruch, T; Stark, C; Trebicka, J | 1 |
| Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Gouya, H; Legmann, P; Mir, O; Pol, S; Ropert, S; Sogni, P; Vignaux, O | 1 |
| Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W | 1 |
| Abraldes, JG; Bosch, J; D'Amico, M; Fernández, M; García-Pagán, JC; García-Pras, E; Mejías, M | 1 |
| Chang, CC; Chen, YC; Hsin, IF; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Lin, YL | 1 |
1 review(s) available for sorafenib and Hypertension, Portal
| Article | Year |
|---|---|
[Therapeutic effect of sorafenib on portal hypertension: research progress and mechanisms].
Topics: Animals; Humans; Hypertension, Portal; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
1 trial(s) available for sorafenib and Hypertension, Portal
| Article | Year |
|---|---|
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Regional Blood Flow; Sorafenib; Survival Analysis | 2011 |
8 other study(ies) available for sorafenib and Hypertension, Portal
| Article | Year |
|---|---|
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
Topics: Animals; Benzenesulfonates; Collateral Circulation; Enteritis; Heme Oxygenase-1; Hepatitis; Hypertension, Portal; Liver; Liver Cirrhosis; Male; Neovascularization, Physiologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Splanchnic Circulation | 2009 |
Antiangiogenic therapy: not just for cancer anymore?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension, Portal; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.
Topics: Animals; Aorta; Benzenesulfonates; Blotting, Western; Hypertension, Portal; Liver; Liver Cirrhosis, Biliary; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; Signal Transduction; Sorafenib | 2009 |
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Cell Proliferation; Cytokines; Down-Regulation; Hemodynamics; Hypertension, Portal; Ligation; Male; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sorafenib; Splanchnic Circulation | 2009 |
Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis.
Topics: Actins; Animals; Apoptosis; Benzenesulfonates; Caspase 3; Colorimetry; DNA Fragmentation; Hepatic Stellate Cells; Histological Techniques; Hypertension, Portal; Immunohistochemistry; Liver; Liver Cirrhosis, Biliary; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Pyridines; Rats; Sorafenib; Vascular Resistance | 2011 |
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Portal Pressure; Protein Kinase Inhibitors; Pyridines; Real-Time Polymerase Chain Reaction; Sorafenib; Syndrome; Treatment Outcome | 2012 |
Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats.
Topics: Animals; Antihypertensive Agents; Benzenesulfonates; Drug Therapy, Combination; Hypertension, Portal; Liver Cirrhosis, Experimental; Male; Niacinamide; Phenylurea Compounds; Propranolol; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib | 2012 |
The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats.
Topics: Animals; Disease Models, Animal; Hepatic Encephalopathy; Humans; Hypertension, Portal; Liver Cirrhosis, Experimental; Male; Niacinamide; Oxidative Stress; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib | 2012 |